DepressionNCT05659472
The Effect of Combination Mindfulness Spiritual-Based Cognitive Therapy Plus Hypnosis in HIV Patients With Depression
A study testing Combination mindfulness spiritual-based cognitive therapy plus hypnosis and Mindfulness-based cognitive therapy in people with Depression, run by Health Technology Institute of Cendekia Utama Kudus at 1 site in Indonesia.
Trial summary
HIV/AIDS patients are at risk for depression, a multifactorial disorder with signs and symptoms that affect the cognitive, affective, behavioral, and somatic areas. This study used Randomized Controlled Clinical Trials (RCT). Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Depression
- What is being tested?
- Combination mindfulness spiritual-based cognitive therapy plus hypnosis and Mindfulness-based cognitive therapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 62 participants
- Where
- 1 siteIndonesia
- Study dates
- 12 Dec 2020to 10 Apr 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- HIV patients with mild-moderate depression;
- Receiving ARV therapy;
- Islam;
- Aged 18-60 years;
- Not taking steroid and serotonin medications;
- Willing to sign the informed consent;
Who cannot join
- Having a history of immune disorders or allergies;
- Currently undergoing hormonal or corticosteroid therapy;
- Patients who used herbal medicine 2 weeks before the study;
- Patients with psychiatric comorbidities and emergency conditions.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Combination Mindfulness Spiritual-Based Cognitive Therapy Plus Hypnosis on Levels of Cortisol, Serotonin, and Depression Degree in HIV Patients With Depression
HIV/AIDS patients are at risk for depression, a multifactorial disorder with signs and symptoms that affect the cognitive, affective, behavioral, and somatic areas. This study used Randomized Controlled Clinical Trials (RCT).
Main hypothesis: A combination of spiritual awareness-based cognitive therapy (MSBCT) plus hypnotic interventions can reduce depression degree scores by reducing cortisol levels and increasing serotonin levels in HIV patients with depression.
Read more
Small hypothesis
- There was a decrease in cortisol levels after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression;
- There was an increase in serotonin levels after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression;
- There was a decrease in depression degree scores after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression;
- There was a higher reduction in cortisol levels in the intervention group compared to the control group in HIV patients with depression;
- There was a higher increase in serotonin levels in the intervention group compared to the control group in HIV patients with depression;
- There was a higher reduction in scores degree of depression in the intervention group compared to the control group in HIV patients with depression;
- Decreased cortisol levels and increased serotonin levels affect depression degree scores in HIV patients with depression;
- MSBCT plus hypnosis combination intervention is a factor that can affect depression degree scores reduction in HIV patients with depression;
Read the detailed description
HIV/AIDS patients are at risk for depression. Evidence shows that depression in HIV/AIDS patients is two to four times higher than in the general population. The prevalence of depression in HIV/AIDS patients varies from 5% to 79% worldwide while the prevalence of depression in Indonesia in 2018 was 21.8% where women (22.3%) had a higher depression rate than men (21,4%). Cases of depression in HIV/AIDS patients are estimated to have a frequency of up to 60% of the total existing cases of depression.
Depressive disorders are caused by biopsychosocial factors and neurotransmitter interactions that affect pathophysiology in a complex manner. The monoaminergic neurotransmitters that play the most role in depression are serotonin (5-HT), norepinephrine (NE), and dopamine (DA). In people with maladaptive PLHIV, cortisol levels in the blood will increase thereby inhibiting cellular and humoral immune responses. This condition causes apoptosis not to occur so that the virus proliferates and spreads rapidly. The progressive effect of HIV/AIDS can infect the central nervous system thereby disrupting the balance of neurotransmitters, accelerating viral replication, and suppressing the immune response so that it can shorten the period of HIV without symptoms. This condition, if not handled properly can reduce the quality of life, weaken physical function and therapeutic effects, as well as higher medical co-morbidities including suicidal behavior.
Although the prevalence is quite high, the efficacy of depression therapy is currently not satisfactory. Less than 50% of depressed patients respond to standard therapy and 70% relapse. Psychopharmacology, psychotherapy, and a combination of the two are effective for treating depression and preventing the recurrence of depression. Psychopharmacological therapy has a shorter impact than psychotherapy. Even today, many people switch from medical therapy to psychotherapy because of the high medical costs and the side effects of pharmacological therapy. Therefore, equipping HIV/AIDS patients with coping strategies to manage physiological and psychological problems is integral to part of providing comprehensive care to HIV/AIDS patients.
The results of the meta-analysis reported that mindfulness-based therapy was effective in reducing symptoms of stress, anxiety, and depression. There is empirical evidence supporting the effectiveness of MBCT in reducing rates of depression and improving the quality of life in chronic disease patients. However, the study results have not been consistent. Two resources that are widely used by patients with mental and physical illnesses are psychotherapy and religion/spirituality. The results of a meta-analysis of 46 spiritual intervention studies reported that patients with spiritually integrated psychotherapy showed positive improvement compared to patients treated only with psychotherapy. On this basis, researchers are trying to develop MBCT psychotherapy with spiritually integrated MBCT, namely a mindfulness-based intervention that integrates Islamic spiritual values (gratitude, patience, pleasure, sincerity, and trustworthiness) with aspects of cognitive behavioral therapy (CBT) and focuses on current conditions, emphasizes acceptance of thoughts, emotions, and behavior by improving thought processes, controlling emotions, and bodily sensations in order to develop self-capacity effectively in dealing with problems.
Positive self-capacity development can occur and be effective when having the basic principles of positive life in the subconscious mind. One way to explore the subconscious mind can be done with hypnosis. Hypnosis is a method of giving suggestions by penetrating the critical factors of the conscious mind into the subconscious mind. Hypnosis has also been shown to be significant in reducing stress, anxiety, and depression scores. Even hypnosis plays a significant role as the first step in treating depression. This makes researchers try to develop a spiritually integrated MBCT psychotherapy combined with hypnosis.
Formulation of the problem Can a combination intervention of mindfulness spiritual-based cognitive therapy (MSBCT) plus hypnosis reduce depression degree scores by reducing cortisol levels and increasing serotonin levels in HIV patients with depression?
Research purposes The research aims to prove that a combination intervention of mindfulness spiritual-based cognitive therapy (MSBCT) plus hypnosis can reduce depression degree scores by decreasing cortisol levels and increasing serotonin levels in HIV patients with depression.
Research hypothesis A combination intervention of mindfulness spiritual-based cognitive therapy (MSBCT) plus hypnosis can reduce depression degree scores by reducing cortisol levels and increasing serotonin levels in HIV patients with depression.
Benefits of research results Provide scientific information about the effects interventions of a combination of mindfulness spiritual-based cognitive therapy (MSBCT) plus hypnosis in reducing cortisol levels, increasing serotonin levels, and reducing the scores degree of depression in HIV patients with depression;
Research methods A randomized controlled trial (RCT). The sampling used a consecutive sampling method, namely a sampling technique based on inclusion and exclusion criteria for selecting predetermined subjects, within a certain period of time until the number of research subjects was fulfilled. After selecting the subjects, the randomization process was carried out using random allocation. The enumerator determined that each group consisted of 31 subjects in the intervention group and 31 subjects in the control group. Randomization used the simple randomization technique, namely by making 62 envelopes, each with 31 envelopes bearing the combination of MSBCT plus Hypnosis and 31 envelopes bearing the words MBCT. All envelopes were randomized and each subject who met the research criteria received one envelope chosen by the enumerator without the researcher and the subject knowing about it. If the envelope taken contains the writing of the MSBCT plus Hypnosis combination then the subject is included in the intervention group sample and the one containing the MBCT writing is included in the control group sample. The intervention was given once a week for 8 weeks. The assessment was carried out 2 times pre and post-intervention by assessing cortisol levels, serotonin levels, and depression degree scores in the control and intervention groups. Statistical tests used the Independent T-test if the data were normally distributed, the Mann Whitney U Test if the data were not normally distributed, and to see the effect of the intervention using a linear regression test.
- Conditions
- Depression
- Being tested
- Combination mindfulness spiritual-based cognitive therapy plus hypnosis, Mindfulness-based cognitive therapy
- Medical subject headings
- Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Combination mindfulness spiritual-based cognitive therapy plus hypnosisBehavioural
Also called Combination MSBCT plus hypnosis
The intervention was divided into eight components in eight sessions, namely (1) psychoeducation and intention, (2) awareness of breathing mindfulness, (3) body scan, (4) comfort training through daily activity/comfort exercises, (5) self-compassion / having a great soul with acceptance, gratitude, and sincerity, (6) planning happiness through independent healthy behavior targets, (7) independent healthy behavior (8) independent healthy behavior evaluation. Each therapeutic component of each session is further divided into three sub-components, namely psychoeducation, training, and hypnosis.
Mindfulness-based cognitive therapyBehavioural
Also called MBCT
The program curriculum consists of the automatic pilot; living in our heads; gathering the scattered mind; recognizing aversion; allowing and letting be; thoughts as thoughts; kindness in action; maintaining and extending new learning.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group = Combination mindfulness spiritual-based cognitive therapy plus hypnosis | Experimental | Given to the intervention group with a frequency of once a week for eight weeks. Each session for 120 minutes or 2 hours with a set of MSBCT intervention packages resulting from modified mindfulness-based cognitive therapy with using the mindfulness concept of Kabat Zinn and the five-step model of mindfulness developed by Vidyamala Burch. Receives: Behavioral: Combination mindfulness spiritual-based cognitive therapy plus hypnosis |
| Control group = Mindfulness-based cognitive therapy | Experimental | Given to the control group with a frequency of once a week for eight weeks. Each session is 90 minutes or 1.5 hours with a set of MBCT intervention packages developed by Teasdale, 2014 Receives: Behavioral: Mindfulness-based cognitive therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Decreased serum cortisol levels
Serum cortisol levels were measured using the ELISA kit catalog method number CO103S in the GAKI laboratory, Faculty of Medicine, Diponegoro University - Semarang - Indonesia
Measured: Before intervention, and 8 weeks after intervention
Increased serum serotonin levels
Serum serotonin levels were measured using the ELISA kit catalog method number E - EL-H0033 in the GAKI laboratory, Faculty of Medicine, Diponegoro University - Semarang - Indonesia
Measured: Before intervention, and 8 weeks after intervention
Decreased degree scores of depression
Depression degree scores were measured using the Beck Depression Inventory (BDI) II
Measured: Before intervention, and 8 weeks after intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Dec 2022
- Study start12 Dec 2020
- Primary completion10 Apr 2021
- Study completion10 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (31)Papers the sponsor has linked to this study.
- Other trials for DepressionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The intervention group was given a combination of mindfulness spiritual-based cognitive therapy (MSBCT) plus hypnosis and the control group was given mindfulness-based cognitive therapy (MBCT).
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 62 participants (actual)
Sponsor and investigators
- Lead sponsor
- Health Technology Institute of Cendekia Utama Kudus
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Eny Pujiati, M.Kes, Principal investigator, Health Technology Institute of Cendekia Utama Kudus - Middle Java - Indonesia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05659472
- Sponsor's protocol ID
- Eny Pujiati
- Status last verified
- Dec 2022
- First submitted
- 5 Dec 2022
- Last updated
- 21 Dec 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: I did'd have a plan share the date
Publications
Asangbeh SL, Sobngwi JL, Ekali GL, Eyoum C, Msellati P. Predictors of depression among patients on art in a rural health district in North West Cameroon. AIDS Care. 2016;28(2):205-8. doi: 10.1080/09540121.2015.1074654. Epub 2015 Aug 19.
PubMed 26288104Bernard C, Dabis F, de Rekeneire N. Prevalence and factors associated with depression in people living with HIV in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One. 2017 Aug 4;12(8):e0181960. doi: 10.1371/journal.pone.0181960. eCollection 2017.
PubMed 28783739Dejman M, Ardakani HM, Malekafzali B, Moradi G, Gouya MM, Shushtari ZJ, Alinaghi SA, Mohraz M. Psychological, Social, and Familial Problems of People Living with HIV/AIDS in Iran: A Qualitative Study. Int J Prev Med. 2015 Dec 23;6:126. doi: 10.4103/2008-7802.172540. eCollection 2015.
PubMed 26900440Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV infected patients: a review. Curr Psychiatry Rep. 2015 Jan;17(1):530. doi: 10.1007/s11920-014-0530-4.
PubMed 25413636Feuillet P, Lert F, Tron L, Aubriere C, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida et les Hepatites Virales (ANRS)-VIH: Enquete sur les personnes atteintes (Vespa2) Study Group. Prevalence of and factors associated with depression among people living with HIV in France. HIV Med. 2017 Jul;18(6):383-394. doi: 10.1111/hiv.12438. Epub 2016 Sep 14.
PubMed 27625202Wang T, Fu H, Kaminga AC, Li Z, Guo G, Chen L, Li Q. Prevalence of depression or depressive symptoms among people living with HIV/AIDS in China: a systematic review and meta-analysis. BMC Psychiatry. 2018 May 31;18(1):160. doi: 10.1186/s12888-018-1741-8.
PubMed 29855289Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS Rep. 2014 Sep;11(3):291-307. doi: 10.1007/s11904-014-0220-1.
PubMed 25038748Peltzer K, Pengpid S. High prevalence of depressive symptoms in a national sample of adults in Indonesia: Childhood adversity, sociodemographic factors and health risk behaviour. Asian J Psychiatr. 2018 Mar;33:52-59. doi: 10.1016/j.ajp.2018.03.017. Epub 2018 Mar 7.
PubMed 29529418Rivera-Rivera Y, Vazquez-Santiago FJ, Albino E, Sanchez MD, Rivera-Amill V. Impact of Depression and Inflammation on the Progression of HIV Disease. J Clin Cell Immunol. 2016 Jun;7(3):423. doi: 10.4172/2155-9899.1000423. Epub 2016 Jun 3.
PubMed 27478681Anacker C. Adult hippocampal neurogenesis in depression: behavioral implications and regulation by the stress system. Curr Top Behav Neurosci. 2014;18:25-43. doi: 10.1007/7854_2014_275.
PubMed 24478038van Bodegom M, Homberg JR, Henckens MJAG. Modulation of the Hypothalamic-Pituitary-Adrenal Axis by Early Life Stress Exposure. Front Cell Neurosci. 2017 Apr 19;11:87. doi: 10.3389/fncel.2017.00087. eCollection 2017.
PubMed 28469557Islam MR, Islam MR, Ahmed I, Moktadir AA, Nahar Z, Islam MS, Shahid SFB, Islam SN, Islam MS, Hasnat A. Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: A case-control study. SAGE Open Med. 2018 May 9;6:2050312118773953. doi: 10.1177/2050312118773953. eCollection 2018.
PubMed 29770218Kambeitz JP, Howes OD. The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. J Affect Disord. 2015 Nov 1;186:358-66. doi: 10.1016/j.jad.2015.07.034. Epub 2015 Jul 31.
PubMed 26281039Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000 Apr;157(4 Suppl):1-45. No abstract available.
PubMed 10767867Geurts DEM, Compen FR, Van Beek MHCT, Speckens AEM. The effectiveness of mindfulness-based cognitive therapy for major depressive disorder: evidence from routine outcome monitoring data. BJPsych Open. 2020 Nov 25;6(6):e144. doi: 10.1192/bjo.2020.118.
PubMed 33234183
Study at a glance
From the registry record, last updated by the sponsor on 21 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Combination Mindfulness Spiritual-Based Cognitive Therapy Plus Hypnosis on Levels of Cortisol, Serotonin, and Depression Degree in HIV Patients With Depression
- ClinicalTrials.gov ID
- NCT05659472
- Acronym / sponsor ID
- Eny Pujiati
- Conditions
- Depression
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 62 participants (actual)
- Lead sponsor
- Health Technology Institute of Cendekia Utama KudusUniversity, hospital or other
- Study start
- 12 Dec 2020 (actual)
- Primary completion
- 10 Apr 2021 (actual)
- Study completion
- 10 Apr 2021 (actual)
- First posted
- 21 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
HIV/AIDS patients are at risk for depression, a multifactorial disorder with signs and symptoms that affect the cognitive, affective, behavioral, and somatic areas. This study used Randomized Controlled Clinical Trials (RCT).
Main hypothesis: A combination of spiritual awareness-based cognitive therapy (MSBCT) plus hypnotic interventions can reduce depression degree scores by reducing cortisol levels and increasing serotonin levels in HIV patients with depression.
Small hypothesis
- There was a decrease in cortisol levels after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression;
- There was an increase in serotonin levels after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression;
- There was a decrease in depression degree scores after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression;
- There was a higher reduction in cortisol levels in the intervention group compared to the control group in HIV patients with depression;
- There was a higher increase in serotonin levels in the intervention group compared to the control group in HIV patients with depression;
- There was a higher reduction in scores degree of depression in the intervention group compared to the control group in HIV patients with depression;
- Decreased cortisol levels and increased serotonin levels affect depression degree scores in HIV patients with depression;
- MSBCT plus hypnosis combination intervention is a factor that can affect depression degree scores reduction in HIV patients with depression;
Detailed description
HIV/AIDS patients are at risk for depression. Evidence shows that depression in HIV/AIDS patients is two to four times higher than in the general population. The prevalence of depression in HIV/AIDS patients varies from 5% to 79% worldwide while the prevalence of depression in Indonesia in 2018 was 21.8% where women (22.3%) had a higher depression rate than men (21,4%). Cases of depression in HIV/AIDS patients are estimated to have a frequency of up to 60% of the total existing cases of depression.
Depressive disorders are caused by biopsychosocial factors and neurotransmitter interactions that affect pathophysiology in a complex manner. The monoaminergic neurotransmitters that play the most role in depression are serotonin (5-HT), norepinephrine (NE), and dopamine (DA). In people with maladaptive PLHIV, cortisol levels in the blood will increase thereby inhibiting cellular and humoral immune responses. This condition causes apoptosis not to occur so that the virus proliferates and spreads rapidly. The progressive effect of HIV/AIDS can infect the central nervous system thereby disrupting the balance of neurotransmitters, accelerating viral replication, and suppressing the immune response so that it can shorten the period of HIV without symptoms. This condition, if not handled properly can reduce the quality of life, weaken physical function and therapeutic effects, as well as higher medical co-morbidities including suicidal behavior.
Although the prevalence is quite high, the efficacy of depression therapy is currently not satisfactory. Less than 50% of depressed patients respond to standard therapy and 70% relapse. Psychopharmacology, psychotherapy, and a combination of the two are effective for treating depression and preventing the recurrence of depression. Psychopharmacological therapy has a shorter impact than psychotherapy. Even today, many people switch from medical therapy to psychotherapy because of the high medical costs and the side effects of pharmacological therapy. Therefore, equipping HIV/AIDS patients with coping strategies to manage physiological and psychological problems is integral to part of providing comprehensive care to HIV/AIDS patients.
The results of the meta-analysis reported that mindfulness-based therapy was effective in reducing symptoms of stress, anxiety, and depression. There is empirical evidence supporting the effectiveness of MBCT in reducing rates of depression and improving the quality of life in chronic disease patients. However, the study results have not been consistent. Two resources that are widely used by patients with mental and physical illnesses are psychotherapy and religion/spirituality. The results of a meta-analysis of 46 spiritual intervention studies reported that patients with spiritually integrated psychotherapy showed positive improvement compared to patients treated only with psychotherapy. On this basis, researchers are trying to develop MBCT psychotherapy with spiritually integrated MBCT, namely a mindfulness-based intervention that integrates Islamic spiritual values (gratitude, patience, pleasure, sincerity, and trustworthiness) with aspects of cognitive behavioral therapy (CBT) and focuses on current conditions, emphasizes acceptance of thoughts, emotions, and behavior by improving thought processes, controlling emotions, and bodily sensations in order to develop self-capacity effectively in dealing with problems.
Positive self-capacity development can occur and be effective when having the basic principles of positive life in the subconscious mind. One way to explore the subconscious mind can be done with hypnosis. Hypnosis is a method of giving suggestions by penetrating the critical factors of the conscious mind into the subconscious mind. Hypnosis has also been shown to be significant in reducing stress, anxiety, and depression scores. Even hypnosis plays a significant role as the first step in treating depression. This makes researchers try to develop a spiritually integrated MBCT psychotherapy combined with hypnosis.
Formulation of the problem Can a combination intervention of mindfulness spiritual-based cognitive therapy (MSBCT) plus hypnosis reduce depression degree scores by reducing cortisol levels and increasing serotonin levels in HIV patients with depression?
Research purposes The research aims to prove that a combination intervention of mindfulness spiritual-based cognitive therapy (MSBCT) plus hypnosis can reduce depression degree scores by decreasing cortisol levels and increasing serotonin levels in HIV patients with depression.
Research hypothesis A combination intervention of mindfulness spiritual-based cognitive therapy (MSBCT) plus hypnosis can reduce depression degree scores by reducing cortisol levels and increasing serotonin levels in HIV patients with depression.
Benefits of research results Provide scientific information about the effects interventions of a combination of mindfulness spiritual-based cognitive therapy (MSBCT) plus hypnosis in reducing cortisol levels, increasing serotonin levels, and reducing the scores degree of depression in HIV patients with depression;
Research methods A randomized controlled trial (RCT). The sampling used a consecutive sampling method, namely a sampling technique based on inclusion and exclusion criteria for selecting predetermined subjects, within a certain period of time until the number of research subjects was fulfilled. After selecting the subjects, the randomization process was carried out using random allocation. The enumerator determined that each group consisted of 31 subjects in the intervention group and 31 subjects in the control group. Randomization used the simple randomization technique, namely by making 62 envelopes, each with 31 envelopes bearing the combination of MSBCT plus Hypnosis and 31 envelopes bearing the words MBCT. All envelopes were randomized and each subject who met the research criteria received one envelope chosen by the enumerator without the researcher and the subject knowing about it. If the envelope taken contains the writing of the MSBCT plus Hypnosis combination then the subject is included in the intervention group sample and the one containing the MBCT writing is included in the control group sample. The intervention was given once a week for 8 weeks. The assessment was carried out 2 times pre and post-intervention by assessing cortisol levels, serotonin levels, and depression degree scores in the control and intervention groups. Statistical tests used the Independent T-test if the data were normally distributed, the Mann Whitney U Test if the data were not normally distributed, and to see the effect of the intervention using a linear regression test.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- The intervention group was given a combination of mindfulness spiritual-based cognitive therapy (MSBCT) plus hypnosis and the control group was given mindfulness-based cognitive therapy (MBCT).
| Arm | Type | Receives |
|---|---|---|
| Intervention group = Combination mindfulness spiritual-based cognitive therapy plus hypnosis | Experimental | Behavioral: Combination mindfulness spiritual-based cognitive therapy plus hypnosisGiven to the intervention group with a frequency of once a week for eight weeks. Each session for 120 minutes or 2 hours with a set of MSBCT intervention packages resulting from modified mindfulness-based cognitive therapy with using the mindfulness concept of Kabat Zinn and the five-step model of mindfulness developed by Vidyamala Burch. |
| Control group = Mindfulness-based cognitive therapy | Experimental | Behavioral: Mindfulness-based cognitive therapyGiven to the control group with a frequency of once a week for eight weeks. Each session is 90 minutes or 1.5 hours with a set of MBCT intervention packages developed by Teasdale, 2014 |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- HIV patients with mild-moderate depression;
- Receiving ARV therapy;
- Islam;
- Aged 18-60 years;
- Not taking steroid and serotonin medications;
Key exclusion criteria (4 listed)
- Having a history of immune disorders or allergies;
- Currently undergoing hormonal or corticosteroid therapy;
- Patients who used herbal medicine 2 weeks before the study;
- Patients with psychiatric comorbidities and emergency conditions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Combination mindfulness spiritual-based cognitive therapy plus hypnosisAlso: Combination MSBCT plus hypnosisThe intervention was divided into eight components in eight sessions, namely (1) psychoeducation and intention, (2) awareness of breathing mindfulness, (3) body scan, (4) comfort training through daily activity/comfort exercises, (5) self-compassion / having a great soul with acceptance, gratitude, and sincerity, (6) planning happiness through independent healthy behavior targets, (7) independent healthy behavior (8) independent healthy behavior evaluation. Each therapeutic component of each session is further divided into three sub-components, namely psychoeducation, training, and hypnosis. | Behavioural | Intervention group = Combination mindfulness spiritual-based cognitive therapy plus hypnosis |
| Mindfulness-based cognitive therapyAlso: MBCTThe program curriculum consists of the automatic pilot; living in our heads; gathering the scattered mind; recognizing aversion; allowing and letting be; thoughts as thoughts; kindness in action; maintaining and extending new learning. | Behavioural | Control group = Mindfulness-based cognitive therapy |
Primary outcome
Decreased serum cortisol levels
Time frame: Before intervention, and 8 weeks after intervention
Serum cortisol levels were measured using the ELISA kit catalog method number CO103S in the GAKI laboratory, Faculty of Medicine, Diponegoro University - Semarang - Indonesia
Increased serum serotonin levels
Time frame: Before intervention, and 8 weeks after intervention
Serum serotonin levels were measured using the ELISA kit catalog method number E - EL-H0033 in the GAKI laboratory, Faculty of Medicine, Diponegoro University - Semarang - Indonesia
Decreased degree scores of depression
Time frame: Before intervention, and 8 weeks after intervention
Depression degree scores were measured using the Beck Depression Inventory (BDI) II
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Dec 2022.
- Results publication: PubMed 26288104Asangbeh SL, Sobngwi JL, Ekali GL, Eyoum C, Msellati P. Predictors of depression among patients on art in a rural health district in North West Cameroon. AIDS Care. 2016;28(2):205-8. doi: 10.1080/09540121.2015.1074654. Epub 2015 Aug 19.
- Results publication: PubMed 28783739Bernard C, Dabis F, de Rekeneire N. Prevalence and factors associated with depression in people living with HIV in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One. 2017 Aug 4;12(8):e0181960. doi: 10.1371/journal.pone.0181960. eCollection 2017.
- Results publication: PubMed 26900440Dejman M, Ardakani HM, Malekafzali B, Moradi G, Gouya MM, Shushtari ZJ, Alinaghi SA, Mohraz M. Psychological, Social, and Familial Problems of People Living with HIV/AIDS in Iran: A Qualitative Study. Int J Prev Med. 2015 Dec 23;6:126. doi: 10.4103/2008-7802.172540. eCollection 2015.
- Results publication: PubMed 25413636Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV infected patients: a review. Curr Psychiatry Rep. 2015 Jan;17(1):530. doi: 10.1007/s11920-014-0530-4.
- Results publication: PubMed 27625202Feuillet P, Lert F, Tron L, Aubriere C, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida et les Hepatites Virales (ANRS)-VIH: Enquete sur les personnes atteintes (Vespa2) Study Group. Prevalence of and factors associated with depression among people living with HIV in France. HIV Med. 2017 Jul;18(6):383-394. doi: 10.1111/hiv.12438. Epub 2016 Sep 14.
- Results publication: PubMed 29855289Wang T, Fu H, Kaminga AC, Li Z, Guo G, Chen L, Li Q. Prevalence of depression or depressive symptoms among people living with HIV/AIDS in China: a systematic review and meta-analysis. BMC Psychiatry. 2018 May 31;18(1):160. doi: 10.1186/s12888-018-1741-8.
- Results publication: PubMed 25038748Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS Rep. 2014 Sep;11(3):291-307. doi: 10.1007/s11904-014-0220-1.
- Results publication: PubMed 29529418Peltzer K, Pengpid S. High prevalence of depressive symptoms in a national sample of adults in Indonesia: Childhood adversity, sociodemographic factors and health risk behaviour. Asian J Psychiatr. 2018 Mar;33:52-59. doi: 10.1016/j.ajp.2018.03.017. Epub 2018 Mar 7.
- Results publication: PubMed 27478681Rivera-Rivera Y, Vazquez-Santiago FJ, Albino E, Sanchez MD, Rivera-Amill V. Impact of Depression and Inflammation on the Progression of HIV Disease. J Clin Cell Immunol. 2016 Jun;7(3):423. doi: 10.4172/2155-9899.1000423. Epub 2016 Jun 3.
- Results publication: PubMed 24478038Anacker C. Adult hippocampal neurogenesis in depression: behavioral implications and regulation by the stress system. Curr Top Behav Neurosci. 2014;18:25-43. doi: 10.1007/7854_2014_275.
- Results publication: PubMed 28469557van Bodegom M, Homberg JR, Henckens MJAG. Modulation of the Hypothalamic-Pituitary-Adrenal Axis by Early Life Stress Exposure. Front Cell Neurosci. 2017 Apr 19;11:87. doi: 10.3389/fncel.2017.00087. eCollection 2017.
- Results publication: PubMed 29770218Islam MR, Islam MR, Ahmed I, Moktadir AA, Nahar Z, Islam MS, Shahid SFB, Islam SN, Islam MS, Hasnat A. Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: A case-control study. SAGE Open Med. 2018 May 9;6:2050312118773953. doi: 10.1177/2050312118773953. eCollection 2018.
- Individual participant dataSharing planned: No. I did'd have a plan share the date
Related trials for Depression
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Not yet recruitingObservational study
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
Superior Semicircular Canal Dehiscence
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Recruiting
Cultural Adaptation of an Online Parenting Intervention to Reduce the Risk of Depression and Anxiety in Adolescents
Risk of Depression and Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eny Pujiati, M.Kes principal investigator
Health Technology Institute of Cendekia Utama Kudus - Middle Java - Indonesia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Combination mindfulness spiritual-based cognitive therapy plus hypnosis and Mindfulness-based cognitive therapy in people with Depression, run by Health Technology Institute of Cendekia Utama Kudus at 1 site in Indonesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Decreased serum cortisol levels (time frame: Before intervention, and 8 weeks after intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05659472, which also lists 31 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Dec 2022.